<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Thirty-six patients with severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> or <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> undergoing bone marrow transplantation or intensive hematologic treatments were randomized to receive gentamicin (1 mg/kg/iv q8h) or <z:chebi fb="0" ids="28864">tobramycin</z:chebi> (1 mg/kg/iv q8h) in combination with carbenecillin (500 mg/kg/day i.v. in 4 doses) and cephalotin (200 mg/kg/day i.v. in 6 doses), at the <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:hpo ids='HP_0001945'>fever</z:hpo> during <z:hpo ids='HP_0001913'>granulocytopenia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Patients in the gentamicin group were treated for a total of 541 patient days (minimum 5, maximum 106), and patients in the <z:chebi fb="0" ids="28864">tobramycin</z:chebi> group for 426 patient days (minimum 9, maximum 48) </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients received oral decontamination, which included the amino <z:chebi fb="0" ids="24400">glycoside</z:chebi> (either gentamicin or <z:chebi fb="0" ids="28864">tobramycin</z:chebi>) given intravenously </plain></SENT>
<SENT sid="3" pm="."><plain>This study showed that 1) no patient had an increase in <z:chebi fb="0" ids="16737">creatinine</z:chebi> level above 1.3 mg % and no patient developed <z:hpo ids='HP_0000083'>renal failure</z:hpo>, 2) there was no difference between gentamicin and <z:chebi fb="0" ids="28864">tobramycin</z:chebi> in the efficacy of treating febrile episodes and/or major <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e>, 3) prolonged intravenous administration (up to 48 consecutive days in the <z:chebi fb="0" ids="28864">tobramycin</z:chebi> group and 106 consecutive days in the gentamicin group) was well tolerated and effective in treating <z:hpo ids='HP_0001945'>fever</z:hpo> of unknown origin in granulocytopenic patients: 45 of 72 febrile episodes resolved while the patients had a granulocyte count below 500/mm3 </plain></SENT>
</text></document>